Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study

Human Pathology - Tập 142 - Trang 15-19 - 2023
Haiying Zhan1, Susan Fineberg2, Peter Podany1, Jennifer Zeng3, Yihong Wang4, Malini Harigopal1, Kamaljeet Singh5
1Yale University School of Medicine, Department of Pathology, New Haven, CT, USA
2Montefiore Medical Center, Department of Pathology, New York, NY, USA
3Icahn School of Medicine at Mount Sinai, Department of Pathology, New York, NY, USA
4Brown University Rhode Island Hospital, Department of Pathology, RI, USA
5Brown University Women and Infants Hospital of Rhode Island, Department of Pathology, RI, USA

Tài liệu tham khảo

Diab, 1999, Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas, J Clin Oncol, 17, 1442, 10.1200/JCO.1999.17.5.1442 Di Saverio, 2008, A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma, Breast Cancer Res Treat, 111, 541, 10.1007/s10549-007-9809-z Lacroix-Triki, 2010, Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type, J Pathol, 222, 282, 10.1002/path.2763 Cao, 2012, Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China, Ann Surg Oncol, 19, 3019, 10.1245/s10434-012-2322-6 Harrison, 2018, An update of mucinous lesions of the breast, Surg Pathol Clin, 11, 61, 10.1016/j.path.2017.09.002 Ginter, 2020, A review of mucinous lesions of the breast, Breast J, 26, 1168, 10.1111/tbj.13878 Gao, 2020, Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: a SEER-based analysis, Breast, 54, 79, 10.1016/j.breast.2020.09.003 Joneja, 2023, The spectrum of mucinous lesions of the breast, Arch Pathol Lab Med, 147, 19, 10.5858/arpa.2022-0054-RA Marrazzo, 2020, Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis, Breast, 49, 87, 10.1016/j.breast.2019.11.002 Semiglazov, 2007, Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer, Cancer, 110, 244, 10.1002/cncr.22789 Alba, 2012, Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study, Ann Oncol, 23, 3069, 10.1093/annonc/mds132 Torrisi, 2007, Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer, Br J Cancer, 97, 802, 10.1038/sj.bjc.6603947 von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595 Tan, 2009, Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer, Am J Surg, 198, 520, 10.1016/j.amjsurg.2009.06.004 Ellis, 2017, Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons Oncology group Z1031 trial (alliance), J Clin Oncol, 35, 1061, 10.1200/JCO.2016.69.4406 Grossman, 2018, Neoadjuvant endocrine therapy: who benefits most?, Surg Oncol Clin, 27, 121, 10.1016/j.soc.2017.07.008 Provenzano, 2015, Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group, Mod Pathol, 28, 1185, 10.1038/modpathol.2015.74 Fisher, 2001, Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer, J Natl Cancer Inst Monogr, 62, 10.1093/oxfordjournals.jncimonographs.a003463 Sataloff, 1995, Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome, J Am Coll Surg, 180, 297 Ogston, 2003, A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival, Breast, 12, 320, 10.1016/S0960-9776(03)00106-1 Symmans, 2007, Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol, 25, 4414, 10.1200/JCO.2007.10.6823 Chollet, 2008, A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN), Cancer J, 14, 128, 10.1097/PPO.0b013e31816bdea2 Pareja, 2019, The genomic landscape of mucinous breast cancer, J Natl Cancer Inst, 111, 737, 10.1093/jnci/djy216 Parikh, 2005, GATA-3 expression as a predictor of hormone response in breast cancer, J Am Coll Surg, 200, 705, 10.1016/j.jamcollsurg.2004.12.025 Baretta, 2013, Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma, Clin Breast Cancer, 13, 156, 10.1016/j.clbc.2012.11.007 Garcia Hernandez, 2018, Her-2 positive mucinous carcinoma breast cancer, case report, Int J Surg Case Rep, 42, 242, 10.1016/j.ijscr.2017.12.025 Didonato, 2018, Invasive mucinous carcinoma of the breast and response patterns after neoadjuvant chemotherapy (NAC), Histopathology, 72, 965, 10.1111/his.13451 Chen, 2021, Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma, Oncol Lett, 22, 771, 10.3892/ol.2021.13032 Barbashina, 2013, Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors, Hum Pathol, 44, 1577, 10.1016/j.humpath.2013.01.003 Sun, 2020, Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast, Mod Pathol, 33, 1945, 10.1038/s41379-020-0554-8